iSpecimen Inc. (ISPC) vs Moleculin Biotech, Inc. (MBRX)
A side-by-side comparison of iSpecimen Inc. and Moleculin Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ISPC
iSpecimen Inc.
$1.06HealthcareDelayed quote: Oct 6, 2026, 11:08 AM EDT
MBRX
Moleculin Biotech, Inc.
$0.46HealthcareDelayed quote: Oct 6, 2026, 11:08 AM EDT
Total return — ISPC vs MBRX
growth of $100 · dividends reinvested · last 5yISPC -100.0% (-82.1%/yr)MBRX -100.0% (-79.7%/yr)MBRX compounded faster over this window
ISPC MBRX
ISPC vs MBRX: by the numbers
- •ISPC is the larger company ($3M vs $2M market cap).
- •Both run net losses; MBRX's is the smaller (0.00% vs -2449.04% net margin).
Metrics side by side
Valuation
| Metric | ISPC | MBRX |
|---|---|---|
| P/S ratio | 5.73 | N/A |
| P/B ratio | 1.54 | 0.21 |
Profitability
| Metric | ISPC | MBRX |
|---|---|---|
| Gross margin | 1.25% | 0.00% |
| Operating margin | -465.42% | 0.00% |
| Net margin | -2449.04% | 0.00% |
| ROE | -657.69% | -261.73% |
| ROIC | -476.39% | -242.25% |
Growth (annualized)
| Metric | ISPC | MBRX |
|---|---|---|
| Revenue CAGR (5Y) | -46.70% | N/A |
| Total return CAGR (5Y) | -81.14% | -78.48% |
Frequently asked
- How have ISPC and MBRX total returns compared?
- Over the past 5 years, ISPC delivered -81.14% and MBRX delivered -78.48% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.